



COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

## Genitourinary

Education & Training Team  
Collaborative Stage Data Collection System  
Version 2.01 (CSv2)

---

---

---

---

---

---

---

---

## Learning Objectives

- Understand rationale behind changes and updates
- Understand use of codes and reporting
- Determine proper code use for accurate reporting
- Understand finding specific documentation
  - SSFs
  - Coding rules

2



---

---

---

---

---

---

---

---

## Outline

- Overview of Prostate Cancer
- Review Collaborative Stage data items for Prostate
- Describe changes to Prostate in CSv2
- Summarize Kidney changes
- Summarize Bladder changes

3



---

---

---

---

---

---

---

---



## Prostate Cancer

---

---

---

---

---

---

---

---

## Prostate Histologies

- Adenocarcinoma – 95%
- Transitional cell morphology – approximately 4%
  - May arise from urothelial lining of prostatic urethra
    - Not included in the Prostate Schema
    - Code to Urethra and use Urethra Schema
- Neuroendocrine morphology – few cases

5



---

---

---

---

---

---

---

---

## Prostate Prognostic Factors

- Clinical predictors
  - PSA – Prostate-specific antigen
  - Gleason score
  - Tumor stage
- Pathologic factors
  - Number/percentage of positive biopsies
  - Surgical margin status

6



---

---

---

---

---

---

---

---

Prostate: Clinical Assessment

Clinically apparent vs inapparent

7 

---

---

---

---

---

---

---

---

Prostate Diagnostic Procedures

- Digital Rectal Exam (DRE)
- Prostate-specific antigen (PSA)
- Transrectal ultrasound (TRUS)
- CT, MRI, Bone Scan
- Biopsy
- Evaluation for metastases

8 

---

---

---

---

---

---

---

---

 COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

CSv2 Changes for Prostate

9

---

---

---

---

---

---

---

---

## What is New in CSv2 for Prostate?

- Collaborative Stage fields
  - Tumor Size: no change
  - Extension: changes from CSv1
  - TS/Ext Eval: clarifications in notes
  - Lymph Nodes: minor change from CSv1
  - LN Eval: no change
  - LN Pos: no change
  - LN Exam: no change
  - Mets at Dx: changes from CSv1
  - Mets Eval: note added

10



---

---

---

---

---

---

---

---

## What is New in CSv2 for Prostate?

- SSF changes at a glance:
  - Site-specific Factor 1 – no changes
  - Site-specific Factor 2 – no changes
  - Site-specific Factor 3 – changes from CSv1
  - Site-specific Factor 4 – no changes; clarifications added
  - Site-specific Factor 5 – Obsolete
  - Site-specific Factor 6 – Obsolete

11



---

---

---

---

---

---

---

---

## New Site-Specific Factors

- Needle Core Biopsy/TURP
  - SSF7: Gleason's Pattern
  - SSF8: Gleason's Score
- Prostatectomy/Autopsy
  - SSF9: Gleason's Pattern
  - SSF10: Gleason's Score
  - SSF11: Gleason's Tertiary Pattern

12



---

---

---

---

---

---

---

---

### New Site-Specific Factors

- Needle Core Biopsies
  - SSF12: Number of Cores Positive
  - SSF13: Number of Cores Examined
  - SSF14: Needle Core Biopsy Findings
- SSF15: Clinical Staging Procedures Performed
- SSF's 16-25: not applicable

13



---

---

---

---

---

---

---

---

### CS Extension – Modifications in CSv2

- Clarifications within the Notes
- Codes are 3 digits, as opposed to 2 digits
- Microscopic bladder neck involvement added
  - New Code 440
  - Maps to T3a
  - Not stated as microscopic: code 500, maps to T4

14



---

---

---

---

---

---

---

---

### CS Extension Codes

- Code 000 (insitu) – maps to TX
  - AJCC does not recognize in situ
- Additional details added to descriptions
  - Ex. Code 100 has added
    - Incidental histologic finding on TURP
    - Stated as clinical T1, NOS

15



---

---

---

---

---

---

---

---

### CS Extension Codes

- Code 150
  - Identified by needle biopsy
  - e.g., for elevated PSA (clinically inapparent)
  - Stated as cT1c
- Codes 200 – 240
  - Clinically / radiographically apparent tumor

16 

---

---

---

---

---

---

---

---

### CS Extension Codes

- Code 300
  - Localized; unknown if clinically apparent or inapparent
- Codes 410 – 700
  - Extension beyond the prostate
- New Codes
  - Code 435: Stated as T3a with no other information on extension
  - Code 440: Microscopic bladder neck involvement
  - Code 470: Combination of 450 + 440

17 

---

---

---

---

---

---

---

---

### CS Extension Codes

- Code 500
  - Bladder neck extension
  - Except microscopic bladder neck involvement
- Code 510 is NEW
  - Stated as T4 with no other information on extension

18 

---

---

---

---

---

---

---

---

### CS Tumor Size/Ext Eval

- Non-standard mapping
- Statements added
  - If criteria met for AJCC Path Staging
- Several notes added for clarification
- Eval code reflects
  - How most extensive disease was determined as coded in CS Extension or SSF3

19




---

---

---

---

---

---

---

---

### CS Tumor Size/Ext Eval

Code	Definition
0	Does not meet criteria for AJCC pathologic staging:  No prostatectomy done. Evaluation based on physical examination. No autopsy evidence used.
1	Does not meet criteria for AJCC pathologic staging:  No prostatectomy done. Evaluation based on endoscopic examination, diagnostic biopsy, TURP, or other invasive techniques. No autopsy evidence used.

20




---

---

---

---

---

---

---

---

### CS Tumor Size/Ext Eval

Code	Definition
2	Meets criteria for AJCC pathologic staging:  No prostatectomy done, but positive biopsy of extraprostatic tissue allows assignment to CS Extension codes 410-700  Not to be used with CS Extension codes 000-300
3	Meets criteria for AJCC pathologic staging:  No prostatectomy done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)

21




---

---

---

---

---

---

---

---

### CS Tumor Size/Ext Eval

Code	Definition
4	<p>Meets criteria for AJCC pathologic staging:</p> <p>Prostatectomy performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed AND evaluation based on evidence acquired before treatment...</p>
5	<p>Does not meet criteria for AJCC y-pathologic (yp) staging:</p> <p>Prostatectomy performed AFTER neoadjuvant therapy and tumor size/extension based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive</p>

22 

---

---

---

---

---

---

---

---

### CS Tumor Size/Ext Eval

Code	Definition
6	<p>Meets criteria for AJCC y-pathologic (yp) staging:</p> <p>Prostatectomy performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologic evidence because pathologic evidence at surgery is more extensive than clinical evidence before treatment.</p>
8	<p>Meets criteria for autopsy (a) staging:</p> <p>Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy).</p>
9	Unknown/Not assessed/Not documented in patient record

23 

---

---

---

---

---

---

---

---

### CS Lymph Nodes

- Code 100 has added "Stated as N1 with no other information on regional lymph nodes"
- For regional nodes only
- Distant nodes coded in CS Mets at DX

24 

---

---

---

---

---

---

---

---

### CS Mets at DX

- No significant changes made
- Two new codes
  - Code 20: Stated as M1a with no other information on distant metastases
  - Code 38: Stated as M1b with no other information on distant metastases
- Code 45 obsolete – converted to 60

25



---

---

---

---

---

---

---

---

### MX Eliminated

- MX has been eliminated from 7<sup>th</sup> Edition
  - Clinical M0
  - Unless clinical or pathologic evidence of mets
- cM only requires history and physical
- Infer cM0 unless known cM1

26



---

---

---

---

---

---

---

---

### CS Mets Eval

- Same as the standard table
  - With addition of Note 2
- Statements added
  - If criteria met for AJCC Path Staging
- Eval code indicates
  - Evidence used to determine highest M

27



---

---

---

---

---

---

---

---

### Mets at Dx-Metastatic Sites

- 4 new fields
  - Bone excluding marrow
  - Lung excluding pleura and pleural fluid
  - Brain excluding spinal cord and other CNS
  - Liver
- Code 0 when CS Mets at Dx is 00
- Code structure
  - 0 – No
  - 1 – Yes
  - 8 – Not applicable
  - 9 – Unknown

28



---

---

---

---

---

---

---

---

### Site-Specific Factor 1

#### Prostatic Specific Antigen (PSA) Lab Value

- No changes
- Note 1: Record highest PSA lab value
- Note 2: Lab values for SSFs 1 and 2
  - From same laboratory test
- Note 3: A lab value expressed in ug/L is equivalent to the same value expressed in ng/ml.

29



---

---

---

---

---

---

---

---

### Site-Specific Factor 2

#### Prostatic Specific Antigen (PSA) Interpretation

- No changes
- Note 1: Use highest PSA lab value
- Note 2: Lab values for SSFs 1 and 2
  - From same laboratory test

30



---

---

---

---

---

---

---

---

### Site-Specific Factor 3: CS Extension – Pathologic Extension

- Codes 020 - 099 made obsolete
- Include information from prostatectomy & autopsy
- Microscopic bladder neck involvement
  - Moved from T4 to T3a
- Code 970 – no prostatectomy

31



---

---

---

---

---

---

---

---

### Site-Specific Factor 4: Prostatic Apex Involvement

- No significant changes
- Notes clarified and definitions provided in Part I

Apex involvement

- **First digit** – clinical status
- **Second digit** – prostatectomy info
- **Third digit** – always 0

32



---

---

---

---

---

---

---

---

### Site-Specific Factor 4: Prostatic Apex Involvement

- Digits are defined
  - 1 - No involvement
  - 2 - Into /arising in
  - 3 - Arising in
  - 4 - Extension into
  - 5 - Unknown

33



---

---

---

---

---

---

---

---

**Site-Specific Factor 5:  
Gleason's Primary Pattern and  
Secondary Pattern Value**

- SSF 5 is OBSOLETE
- Old data are retained
- See SSFs 7-11 to record Gleason information
- Use code 988 (not applicable)

34



---

---

---

---

---

---

---

---

**Site-Specific Factor 6:  
Gleason's Score**

- SSF 6 is also OBSOLETE
- Old data are retained
- See SSFs 7-11 to record Gleason information
- Use code 988 (not applicable)

35



---

---

---

---

---

---

---

---

**Site-Specific Factor 7:  
Gleason's Primary Pattern and  
Secondary Pattern Value on Needle  
Core Biopsy/TURP**

- From needle core biopsy or TURP ONLY
  - Gleason's primary and secondary patterns
- Code the highest or most aggressive pattern
- Prostatectomy Gleason's patterns in SSF 9

36



---

---

---

---

---

---

---

---

### Site-Specific Factor 8: Gleason's Score on Needle Core Biopsy/TURP

- From the needle core biopsy or TURP ONLY
  - Gleason's score
- Code highest or most aggressive score
- Prostatectomy Gleason's score in SSF 10

37



---

---

---

---

---

---

---

---

### Site-Specific Factor 9: Gleason's Primary Pattern and Secondary Pattern Value on Prostatectomy/Autopsy

- From Prostatectomy or Autopsy ONLY
  - Gleason's primary pattern and secondary pattern
- Tertiary pattern in SSF 11

38



---

---

---

---

---

---

---

---

### Site-Specific Factor 10: Gleason's Score on Prostatectomy/Autopsy

- From Prostatectomy or Autopsy ONLY
  - Gleason's Score
- Tertiary pattern in SSF 11

39



---

---

---

---

---

---

---

---

**Site-Specific Factor 11:  
Gleason's Tertiary Pattern on  
Prostatectomy/Autopsy**

- High tertiary Gleason pattern
  - Indicates a worse outcome
- From prostatectomy or Autopsy ONLY
  - Gleason's tertiary pattern

40



---

---

---

---

---

---

---

---

**Site-Specific Factor 11:  
Gleason's Tertiary Pattern on  
Prostatectomy/Autopsy**

- Code 010-050
  - For Patterns 1 - 5
- Code 998
  - No prostatectomy/autopsy performed
- Code 999
  - Unknown; Not documented in the patient record

41



---

---

---

---

---

---

---

---

**Site-Specific Factor 12: Number of  
Cores Positive**

- Code 000 - All negative
- Code 001-024 - 1 - 24 cores positive
- Code 025 - 25 or more cores positive
- Code 991 - Positive, number unknown
- Code 998 – No needle core biopsy performed
- Code 999 – Unknown, Not documented

42



---

---

---

---

---

---

---

---

### Site-Specific Factor 13: Number of Cores Examined

- Code 000 - No cores examined
- Code 001-024 - 1 - 24 cores examined
- Code 025 - 25 or more cores examined
- Code 991 - Examined, number unknown
- Code 998 – No needle core biopsy performed
- Code 999 – Unknown, Not documented

43



---

---

---

---

---

---

---

---

### Site-Specific Factor 14: Needle Core Biopsy Findings

- Code 000 – Negative needle core biopsy findings
- Code 010 – Positive findings in one lobe/side
- Code 020 – Positive findings in both lobes/sides
- Code 030 – Positive findings; location not stated
- Code 050 - Positive findings beyond prostate
- Code 998 - None performed
- Code 999 – Unknown, Not documented

44



---

---

---

---

---

---

---

---

### Site-Specific Factor 15: Clinical Staging Procedures Performed

- Code 000 - No DRE and no imaging
- Code 010 – Digital rectal exam (DRE) only; imaging not performed or unknown if performed
- Code 020 - Imaging only; DRE not performed or unknown if performed
- Code 030 - 020 + 010; DRE and imaging performed
- Code 999 – Unknown, Not documented

45



---

---

---

---

---

---

---

---

## Site Specific Factors 16 - 25

- No additional site-specific factors for Prostate
- Assign code 988 for SSF 16 to 25

46



---

---

---

---

---

---

---

---



COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

## Changes to other Genitourinary Sites

---

---

---

---

---

---

---

---

## What is New in CSv2 for Kidney?

- Collaborative Stage fields
  - Tumor Size: changes from CSv1
  - Extension: changes from CSv1
  - TS/Ext Eval: no change
  - Lymph Nodes: minor change from CSv1
  - LN Eval: no change
  - LN Pos: no change
  - LN Exam: no change
  - Mets at Dx: minor change from CSv1
  - Mets Eval: no change

48



---

---

---

---

---

---

---

---

## KIDNEY: Summary of Changes

- CS Tumor Size
  - T1 and T2 assigned based on tumor size
  - ‘Stated as T’ codes added
- CS Extension
  - Ipsilateral adrenal involvement upstaged
  - Renal vein involvement downstaged

49



---

---

---

---

---

---

---

---

## KIDNEY: Summary of Changes

- CS Lymph Nodes
  - Nodal involvement simplified
  - N2 category removed
- CS Mets at Dx
  - No significant changes

50



---

---

---

---

---

---

---

---

## KIDNEY: Site-Specific Factor Changes

- New Site-Specific Factors
  - SSF1: Invasion Beyond Capsule
  - SSF2: Vein Involvement
  - SSF3: Ipsilateral Adrenal Gland Involvement
  - SSF4: Sarcomatoid Features
  - SSF5: Histologic Tumor Necrosis
  - SSF6: Fuhrman Nuclear Grade
  - SSF7: Size of Metastasis in Lymph Nodes
  - SSF8: Extranodal Extension

51



---

---

---

---

---

---

---

---

## KIDNEY: Site-Specific Factor Example

- Fuhrman Nuclear Grade – SSF 6
  - 000 None; no grade provided on pathology specimen
  - 010 Grade 1
  - 020 Grade 2
  - 030 Grade 3
  - 040 Grade 4
  - 998 No histologic exam of primary site
  - 999 Unknown, not documented in record

52



---

---

---

---

---

---

---

---

## What is New in CSv2 for Bladder?

- Collaborative Stage fields
  - Tumor Size: no change
  - Extension: minor changes from CSv1
  - TS/Ext Eval: no change
  - Lymph Nodes: changes from CSv1
  - LN Eval: no change
  - LN Pos: no change
  - LN Exam: no change
  - Mets at Dx: changes from CSv1
  - Mets Eval: no change

53



---

---

---

---

---

---

---

---

## BLADDER: Summary of Changes

- CS Lymph Node
  - N1: single positive node
  - N2: multiple positive nodes
  - N3: common iliac node involvement
- Common Iliac Nodes
  - Changed to regional

54



---

---

---

---

---

---

---

---

## BLADDER: Site-Specific Factor Changes

- New Site-Specific Factors
  - SSF1: WHO/ISUP Grade
  - SSF2: Size of Metastasis in Lymph Node
  - SSF3: Extranodal Extension

55



---

---

---

---

---

---

---

---

## BLADDER: Site-Specific Factor Example

- WHO/ISUP Grade – SSF 1
  - 010 Low grade urothelial carcinoma
  - 020 High grade urothelial carcinoma
  - 991 Not applicable; morphology is NOT urothelial
  - 998 No histologic examination of primary site
  - 999 Unknown, not documented in record

56



---

---

---

---

---

---

---

---

## Conclusion

- CS Extension & CS Lymph Nodes are 3-digits
- Clarifications to notes
- Extraprostatic invasion w/ microscopic bladder neck invasion now T3a
- SSF 3 restructured
  - 9 New SSFs for Prostate – 2 Obsolete
  - 8 New SSFs for Kidney
  - 3 New SSFs for Bladder

57



---

---

---

---

---

---

---

---

## Inquiry & Response System

- Submit questions to Inquiry & Response System
  - Allows tracking for educational purposes
  - Provides information for all



- <http://web.facs.org/coc/default.htm>

58



---

---

---

---

---

---

---

---

## Questions?

59



---

---

---

---

---

---

---

---

## American Joint Committee on Cancer Contact Information

Karen A. Pollitt – Manager

email: [kpollitt@facs.org](mailto:kpollitt@facs.org)

phone: 312-202-5313

Donna M. Gress, RHIT, CTR – Technical Specialist

email: [dgress@facs.org](mailto:dgress@facs.org)

phone: 312-202-5410

General Inquiries can be directed to [AJCC@facs.org](mailto:AJCC@facs.org)

Collaborative Stage Data Collection System Web Site

[www.cancerstaging.org/cstage](http://www.cancerstaging.org/cstage)

60



---

---

---

---

---

---

---

---